Clinical trial
A Pilot Study of Alemtuzumab (Campath[R]) in Patients With Myelodysplastic…
NCT00217594 · National Heart, Lung, and Blood Institute (NHLBI), NIH · Completed
Key facts
| NCT number | NCT00217594 |
|---|---|
| Title | A Pilot Study of Alemtuzumab (Campath[R]) in Patients With Myelodysplastic Syndrome |
| Official title | A Pilot Study of Alemtuzumab (Campath[R]) in Patients With Myelodysplastic Syndrome (MDS) |
| Lead sponsor | National Heart, Lung, and Blood Institute (NHLBI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Myelodysplastic Syndromes |
| Intervention type | Drug |
| Interventions | Alemtuzumab (Campath) |
| Enrollment | 40 |
| Start date | Jul 21, 2005 |
| Primary completion | Feb 6, 2017 |
| Completion | Feb 6, 2017 |
| First posted | Sep 22, 2005 |
| Last update posted | Oct 30, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: